XLO

Xilio Therapeutics, Inc. (XLO) - Q2 2026 10-Q Summary

Business Context and Reporting Period

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company developing masked immuno-oncology (I-O) therapies. This report covers the quarterly period ended June 30, 2026. The company is classified as an emerging growth company and a smaller reporting company. Its primary focus is on advancing product candidates including XTX501 (bispecific PD-1/masked IL-2), efarindodekin alfa (masked IL-12), and masked T cell engagers.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Collaboration and license revenue increased significantly to $18.7 million in Q2 2026 from $8.1 million in Q2 2025. This was driven by revenue recognition under agreements with AbbVie and Gilead, including a $6.0 million development milestone achieved with AbbVie in Q2 2026.
• Reduced Net Loss: The net loss narrowed to $6.4 million in Q2 2026 compared to $15.8 million in Q2 2025, primarily due to higher revenue recognition offsetting operating expenses.
• Operating Expenses: Total operating expenses were relatively flat quarter-over-quarter ($22.2 million in Q2 2026 vs. $22.5 million in Q2 2025). However, on a year-to-date basis, R&D expenses increased by $10.8 million to $34.4 million, driven by increased manufacturing and clinical trial startup activities for XTX501 and preclinical work on masked T cell engagers.
• Capital Structure: The company completed a follow-on offering of prefunded warrants in February 2026, raising net proceeds of $37.3 million. Additionally, the company issued shares under its At-The-Market (ATM) facility, raising $4.6 million in Q2 2026.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management anticipates that existing cash ($136.0 million) plus the $6.0 million AbbVie milestone received in Q3 2026 will fund operations into the first quarter of 2028. This estimate excludes potential proceeds from the exercise of Series C warrants (up to $36.2 million) and future milestones.
• Development Milestones:
  • XTX501: Phase 1 dosing expected to initiate in H2 2026; initial data expected in H2 2027.
  • Efarindodekin alfa: Ongoing Phase 2 trial; option data package delivery to Gilead expected in H1 2027.
  • Masked T Cell Engagers: IND submissions for CLDN18.2 and PSMA+STEAP1 programs planned for H2 2027.
• Key Risks:
  • Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require substantial additional capital to complete development.
  • Manufacturing Dependencies: Reliance on WuXi Biologics in China for manufacturing exposes the company to geopolitical risks, including the BIOSECURE Act and potential trade restrictions.
  • Regulatory Uncertainty: Risks related to FDA guidance changes, potential government shutdowns, and the complexity of obtaining approval for novel masked biologics.
  • Warrant Liabilities: The company has significant warrant liabilities ($30.2 million) classified as Level 3 fair value measurements, which can cause volatility in net income due to fair value adjustments.

Investor Verification Checklist

• Verify the timing and certainty of the $6.0 million AbbVie milestone payment receipt (noted as received in Q3 2026).
• Assess the likelihood of Series C warrant exercises (3.4 million warrants outstanding at $10.50 strike) to determine potential dilution or cash inflow.
• Review the specific terms of the WuXi Biologics manufacturing agreements and the company's contingency plans regarding the BIOSECURE Act and U.S.-China trade tensions.
• Monitor the progress of the XTX501 Phase 1 trial initiation in H2 2026 as a critical near-term catalyst.
• Confirm the burn rate relative to the stated runway into Q1 2028, considering potential increases in R&D spend for upcoming IND filings.